Investigating the role of a protein in brain damage after lack of blood flow.
CaMKII in global cerebral ischemia: mechanisms and therapeutic intervention
This study is looking at how a protein called CaMKII can harm brain cells when the brain doesn't get enough blood, like during a cardiac arrest, and it’s testing whether blocking this protein can help protect those cells and improve recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10996193 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific protein, CaMKII, contributes to brain cell damage during global cerebral ischemia, a condition where the brain is deprived of blood flow. The researchers are exploring how inhibiting this protein can protect brain cells and improve recovery after events like cardiac arrest. By using animal models that simulate human conditions, they aim to identify effective treatment strategies that could be applied in clinical settings. The study will also examine the timing and effectiveness of these interventions in conjunction with existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have suffered from cardiac arrest or similar conditions that lead to global cerebral ischemia.
Not a fit: Patients who do not have a history of cardiac arrest or related ischemic events may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce brain damage and improve recovery outcomes for patients who experience cardiac arrest.
How similar studies have performed: Previous research has shown promising results with similar approaches in animal models, indicating potential for success in human applications.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Bayer, K. Ulrich — University of Colorado Denver
- Study coordinator: Bayer, K. Ulrich
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.